Pharmaceutical firm Merck & Co. Inc. (NYSE: MRK) reported web revenue for the second quarter of 2024, on an adjusted foundation, in comparison with a loss final 12 months. Each gross sales and earnings exceeded the market’s expectations.
Second-quarter worldwide gross sales elevated 7% year-over-year to $16.11 billion, primarily reflecting continued development within the gross sales of vaccines and oncology/cardiovascular merchandise. Wall Avenue was on the lookout for slower development.
The corporate reported a web revenue of $5.46 billion or $2.14 per share for the June quarter, in comparison with a lack of $5.98 billion or $2.35 per share within the prior-year interval. On an adjusted foundation, web revenue was $2.28 per share, in comparison with a lack of $2.06 per share within the second quarter of 2023. The underside line topped expectations.
“I am proud of our dedicated teams around the world that are working tirelessly to advance our deep pipeline as we continue delivering innovation that solves unmet medical needs,” mentioned Merck’s CEO Robert Davis.
